Therapeutic vaccines that treat cancers with the help of the patient's own immune system
signify a feasible option for active immunotherapy against the disease. Dendritic cells (DCs) …

The use of dendritic cells (DCs) for tumor immunotherapy represents a powerful approach
for harnessing the patient's own immune system to eliminate tumor cells. However …

Dendritic cell (DC)-based vaccines against cancer have been extensively developed over
the past two decades. Typically DC-based cancer immunotherapy entails loading patient …

Since the discovery of dendritic cells (DCs) in 1973 by Ralph Steinman, a tremendous
amount of knowledge regarding these innate immunity cells has been accumulating. Their …

Dendritic cells (DCs) are believed to be the most potent antigen-presenting cells able to link
the innate and adaptive immune systems. Many studies have focused on different …

Dendritic cells (DCs) were initially described in 1973 by Ralph Steinman, who observed in
mouse spleen a subpopulation of cells with a striking dendritic morphology. DCs originate …

Dendritic cells (DCs) play a pivotal role in the orchestration of immune responses, and are
thus key targets in cancer vaccine design. Since the 2010 FDA approval of the first cancer …

Dendritic cells (DCs) are the most powerful professional antigen-presenting cells and are
unique in their capability to initiate, maintain and regulate the intensity of primary immune …

Because of their unique role in linking the innate and adaptive immune systems, dendritic
cells (DCs) have been a logical focus for novel immunotherapies. However, strategies …

Dendritic cells (DCs) are potent antigen presenting cells that exist in virtually every tissue,
and from which they capture antigens and migrate to secondary lymphoid organs where …